Article
Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Oncotarget - 4 Jul 2017
Chen Min, Turhan Ali G, Ding Hongxia, Lin Qingcong, Meng Kun, Jiang Xiaoyan
Abstract excerpt
Treatment of BCR-ABL+ human leukemia has been significantly improved by ABL tyrosine kinase inhibitors (TKIs), but they are not curative for most patients and relapses are frequently associated with BCR-ABL mutations, warranting new targets for improved treatments. We have now demonstrated that protein expression of human estrogen receptor alpha 36 (ERα36), an alternative splicing variant of human estrogen...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.